查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1961272

骨髓發育不良症候群治療市場－全球產業規模、佔有率、趨勢、機會、預測：按治療類型、最終用戶、地區和競爭格局分類，2021-2031年

Myelodysplastic Syndrome Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Treatment Type, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球骨髓發育不良症候群(MDS) 治療市場預計將從 2025 年的 30.4 億美元成長到 2031 年的 43.3 億美元，複合年成長率為 6.07%。

骨髓增生異常綜合症（MDS）的治療方法多種多樣，從去甲基化藥物和免疫調節劑到造血幹細胞移植，旨在恢復正常的骨髓功能並防止其進展為急性骨髓性白血病。全球人口老化是推動此疾病發展的主要因素。這些骨髓功能障礙疾病通常與老齡化有關，而診斷技術的進步正在發現以前未被發現的病例，從而確保了對醫療干預的持續需求。

市場概覽
預測期 2027-2031
市場規模：2025年 30.4億美元
市場規模：2031年 43.3億美元
複合年成長率：2026-2031年 6.07%
成長最快的細分市場 醫院和診所
最大的市場 北美洲

儘管存在這些有利條件，但該疾病的臨床表現多樣性使得準確診斷和標靶治療的選擇變得困難，為市場發展帶來了重大障礙。這種複雜性往往導致患者治療依從性低，並為患者管理帶來許多挑戰。例如，根據MDS聯盟2024年報告，45%的患者不清楚自己的MDS亞型，這種診斷上的不確定性阻礙了先進療法的有效應用，並限制了該專科領域的潛在成長。

市場促進因素

一系列創新療法的湧現正從根本上改變全球骨髓增生異常綜合症（MDS）的治療市場。治療標準正從單純的支持性治療轉向緩解疾病療法。研發人員正優先研究端粒酶抑制劑和其他新型作用機制，以克服傳統促紅血球生成劑的不足，尤其是在輸血依賴型患者身上。鑑於該疾病預後不良，這項創新至關重要。美國臨床腫瘤學會（ASCO）於2024年3月報告稱，MDS的5年相對存活率約為37%。監管方面的進展也為此發展提供了支持；例如，Geron公司於2024年6月宣布，FDA已核准Litero（伊美替司他）。 IMerge III期臨床試驗表明，伊美替司他治療可使39.8%的患者在至少8週內擺脫紅血球輸注依賴。

同時，標靶治療的興起正在推動市場成長，尤其是在一線治療領域，因為它們能夠更精準地治療特定疾病亞型。這些療法針對特定的生物路徑或成熟障礙，與傳統的特異性療法相比，其應用日益廣泛，並創造了顯著的商業性價值。這一轉變也體現在主要企業的財務表現中。 2024年10月，百時美施貴寶公司報告稱，其Reblozyl®的全球銷售額成長了80%，達到4.47億美元。這主要得益於第一線MDS治療的強勁需求，也顯示市場正在圍繞那些與傳統治療方法相比療效更佳的高價值藥物療法進行整合。

市場挑戰

骨髓發育不良症候群綜合症 (MDS) 固有的臨床異質性是全球治療市場成長的主要阻礙因素。由於疾病表現出不同的生物學特徵和進展速度，醫生往往難以做出準確診斷並確定最佳治療策略。這種差異性導致治療延誤和次優治療方案的選擇，阻礙了標靶治療的應用，並給尋求廣泛分銷針對特定生物學亞型藥物的製造商設置了障礙。

這種診斷的複雜性導致患者群體分散，並限制了先進療法的獲利能力。由於缺乏準確的分類，患者往往被分配到一般支持治療，而不是接受高價值的積極治療。美國癌症協會估計，到2025年，美國將新增13,000例骨髓增生異常綜合症（MDS）病例，但由於缺乏標準化的疾病表現，診斷的不確定性限制了更有效醫療干預措施的持續應用，市場也無法充分滿足這一需求。

市場趨勢

口服低甲基化藥物的出現顯著改變了治療環境，將治療方式從靜脈注射轉變為居家照護。這一趨勢提供了一種更便捷的選擇，減輕了長期腸外給藥帶來的後勤挑戰，並有助於提高治療依從性，減少住院次數。真實世界的臨床數據支持這種轉變的安全性。根據2025年11月美國血液學會（ASH）的摘要，接受口服Decitabine和塞達扎瑞聯合治療的患者在前兩個療程中發燒性嗜中性白血球低下症症的發生率顯著降低（17%），這表明與腸外給藥組（55%）相比，住院風險可能降低。

另一方面，聯合治療的臨床試驗在市場上迅速增加，製藥公司正在檢驗具有新型作用機制的藥物（例如BCL-2抑制劑）與去甲基化藥物聯合使用，以克服單藥治療的限制。這項研究旨在透過協同作用提高高風險族群的生存率，但獲得具有統計意義的臨床結果仍然困難重重。例如，2025年6月，艾伯維公司宣布其針對新診斷高風險患者的III期主要臨床試驗「VERONA」（該試驗將維奈托克與Azacitidine聯合使用）未能達到其主要終點－總生存期，風險比為0.908。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球骨髓發育不良症候群（MDS）治療市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依類型分類的治療方法（幹細胞移植、免疫療法、化療、免疫調節藥物、抗貧血藥物、其他）
    • 依最終使用者（醫院/診所、門診中心、其他）分類
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美骨髓發育不良症候群（MDS）治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲骨髓發育不良症候群（MDS）治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區骨髓發育不良症候群（MDS）治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲骨髓發育不良症候群（MDS）治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲骨髓發育不良症候群（MDS）治療市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球骨髓發育不良症候群（MDS）治療市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • AbbVie Inc.
  • Accord Healthcare Limited
  • Bristol-Myers Squibb Company
  • Jazz Pharmaceuticals Inc.
  • Novartis AG
  • Lupin Limited
  • Otsuka America Pharmaceutical Inc.
  • Takeda Pharmaceutical Company Limited
  • Astex Therapeutics Limited
  • Pfizer Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 19092

The Global Myelodysplastic Syndrome (MDS) Treatment Market is projected to expand from USD 3.04 Billion in 2025 to USD 4.33 Billion by 2031, reflecting a compound annual growth rate of 6.07%. Treatments for MDS, which range from hypomethylating agents and immunomodulators to hematopoietic stem cell transplantation, aim to reinstate normal bone marrow activity and halt the progression to acute myeloid leukemia. A key factor driving this growth is the aging global population, as these bone marrow failure disorders are frequently associated with advancing age, while improved diagnostic techniques are uncovering previously undetected cases, ensuring a steady demand for medical interventions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 3.04 Billion
Market Size 2031USD 4.33 Billion
CAGR 2026-20316.07%
Fastest Growing SegmentHospitals & Clinics
Largest MarketNorth America

Despite these favorable conditions, the market confronts substantial hurdles due to the clinical heterogeneity of the disease, which makes accurate diagnosis and targeted therapy selection difficult. This complexity often results in poor treatment adherence and significant management challenges for patients. For example, the MDS Alliance reported in 2024 that 45% of patients were unaware of their specific MDS subtype, a lack of diagnostic clarity that limits the effective use of advanced therapies and restricts the potential growth of the specialized treatment sector.

Market Driver

A strong pipeline of innovative therapeutic agents is fundamentally transforming the Global MDS Treatment Market, moving the standard of care from merely supportive measures to disease-modifying interventions. Developers are prioritizing telomerase inhibitors and other new mechanisms to overcome the shortcomings of traditional erythropoiesis-stimulating agents, especially for patients dependent on transfusions. This innovation is vital given the disease's poor prognosis; the American Society of Clinical Oncology noted in March 2024 that the 5-year relative survival rate is around 37%. Regulatory successes underscore this progress, such as Geron Corporation's June 2024 announcement regarding the FDA approval of Rytelo, where the IMerge Phase 3 trial showed a 39.8% red blood cell transfusion independence rate for at least eight weeks with imetelstat.

In parallel, the rise of targeted and immunomodulatory therapies is fueling market growth by allowing for more precise treatment of specific disease subtypes, particularly in first-line settings. These therapies, which address specific biological pathways and maturation defects, are seeing increased adoption and generating significant commercial value over older, non-specific treatments. This shift is reflected in the financial results of major players; Bristol Myers Squibb reported in October 2024 that worldwide revenues for Reblozyl jumped 80% to $447 million, driven by robust demand in first-line MDS treatment, indicating a market consolidation around high-value pharmacotherapies that deliver better outcomes than traditional care.

Market Challenge

The clinical heterogeneity inherent in Myelodysplastic Syndromes poses a major constraint on the growth of the global treatment market. Since the disease manifests with diverse biological features and progression speeds, physicians often struggle to pinpoint accurate diagnoses and determine the best therapeutic courses. This variability frequently results in delayed treatment or the choice of suboptimal management plans, thereby dampening the utilization of targeted pharmacotherapies and creating barriers for manufacturers attempting to widely distribute drugs tailored to specific biological subtypes.

Such diagnostic complexity fragments the patient base and curbs the revenue potential for advanced treatments. Without precise classification, patients are frequently assigned to general supportive care rather than receiving high-value active therapies. Although the American Cancer Society estimates that 13,000 new MDS cases will be diagnosed in the United States in 2025, the absence of a standardized disease presentation prevents the market from fully addressing this demand, as diagnostic uncertainty limits the consistent prescription of premium medical interventions.

Market Trends

The shift toward Oral Hypomethylating Agents is significantly reshaping the treatment landscape by moving care from intravenous infusions to home-based regimens. This trend mitigates the logistical challenges of chronic parenteral therapies, providing a more convenient option that aids adherence and decreases the frequency of clinic visits. Real-world data supports the safety of this transition; an abstract from the American Society of Hematology in November 2025 revealed that patients on oral decitabine-cedazuridine had a notably lower incidence of febrile neutropenia during the first two cycles-17% compared to 55% for those on parenteral agents-highlighting the potential for fewer hospitalizations.

At the same time, the market is characterized by a surge in Combination Therapy Clinical Trials, where pharmaceutical companies are testing hypomethylating agents paired with novel mechanisms like BCL-2 inhibition to surpass the efficacy limits of monotherapy. While this research aims to enhance survival in higher-risk groups through synergistic pathways, achieving statistically significant clinical results remains difficult. For instance, AbbVie announced in June 2025 that the pivotal Phase 3 VERONA trial, testing venetoclax combined with azacitidine in newly diagnosed higher-risk patients, failed to meet its primary overall survival endpoint, showing a hazard ratio of 0.908.

Key Market Players

  • AbbVie Inc.
  • Accord Healthcare Limited
  • Bristol-Myers Squibb Company
  • Jazz Pharmaceuticals Inc.
  • Novartis AG
  • Lupin Limited
  • Otsuka America Pharmaceutical Inc.
  • Takeda Pharmaceutical Company Limited
  • Astex Therapeutics Limited
  • Pfizer Inc.

Report Scope

In this report, the Global Myelodysplastic Syndrome (MDS) Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Myelodysplastic Syndrome (MDS) Treatment Market, By Treatment Type

  • Stem Cell Transplant
  • Immune Treatments
  • Chemotherapy
  • Immunomodulatory Drugs
  • Anti-anemics
  • Others

Myelodysplastic Syndrome (MDS) Treatment Market, By End User

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others

Myelodysplastic Syndrome (MDS) Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Myelodysplastic Syndrome (MDS) Treatment Market.

Available Customizations:

Global Myelodysplastic Syndrome (MDS) Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Myelodysplastic Syndrome (MDS) Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Treatment Type (Stem Cell Transplant, Immune Treatments, Chemotherapy, Immunomodulatory Drugs, Anti-anemics, Others)
    • 5.2.2. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Myelodysplastic Syndrome (MDS) Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Treatment Type
    • 6.2.2. By End User
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Treatment Type
        • 6.3.1.2.2. By End User
    • 6.3.2. Canada Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Treatment Type
        • 6.3.2.2.2. By End User
    • 6.3.3. Mexico Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Treatment Type
        • 6.3.3.2.2. By End User

7. Europe Myelodysplastic Syndrome (MDS) Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Treatment Type
    • 7.2.2. By End User
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Treatment Type
        • 7.3.1.2.2. By End User
    • 7.3.2. France Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Treatment Type
        • 7.3.2.2.2. By End User
    • 7.3.3. United Kingdom Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Treatment Type
        • 7.3.3.2.2. By End User
    • 7.3.4. Italy Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Treatment Type
        • 7.3.4.2.2. By End User
    • 7.3.5. Spain Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Treatment Type
        • 7.3.5.2.2. By End User

8. Asia Pacific Myelodysplastic Syndrome (MDS) Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Treatment Type
    • 8.2.2. By End User
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Treatment Type
        • 8.3.1.2.2. By End User
    • 8.3.2. India Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Treatment Type
        • 8.3.2.2.2. By End User
    • 8.3.3. Japan Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Treatment Type
        • 8.3.3.2.2. By End User
    • 8.3.4. South Korea Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Treatment Type
        • 8.3.4.2.2. By End User
    • 8.3.5. Australia Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Treatment Type
        • 8.3.5.2.2. By End User

9. Middle East & Africa Myelodysplastic Syndrome (MDS) Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Treatment Type
    • 9.2.2. By End User
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Treatment Type
        • 9.3.1.2.2. By End User
    • 9.3.2. UAE Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Treatment Type
        • 9.3.2.2.2. By End User
    • 9.3.3. South Africa Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Treatment Type
        • 9.3.3.2.2. By End User

10. South America Myelodysplastic Syndrome (MDS) Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Treatment Type
    • 10.2.2. By End User
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Treatment Type
        • 10.3.1.2.2. By End User
    • 10.3.2. Colombia Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Treatment Type
        • 10.3.2.2.2. By End User
    • 10.3.3. Argentina Myelodysplastic Syndrome (MDS) Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Treatment Type
        • 10.3.3.2.2. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Myelodysplastic Syndrome (MDS) Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. AbbVie Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Accord Healthcare Limited
  • 15.3. Bristol-Myers Squibb Company
  • 15.4. Jazz Pharmaceuticals Inc.
  • 15.5. Novartis AG
  • 15.6. Lupin Limited
  • 15.7. Otsuka America Pharmaceutical Inc.
  • 15.8. Takeda Pharmaceutical Company Limited
  • 15.9. Astex Therapeutics Limited
  • 15.10. Pfizer Inc.

16. Strategic Recommendations

17. About Us & Disclaimer